Sonnet BioTherapeutics Holdings, Inc. has announced a special meeting for its stockholders to vote on a significant business combination agreement with Rorschach I LLC and Hyperliquid Strategies Inc. This agreement, initially entered on July 11, 2025, and amended on September 22, 2025, involves a series of mergers that will result in Sonnet becoming a wholly owned subsidiary of a new entity, Pubco. The transaction is expected to issue approximately 155 million shares of Pubco Common Stock and warrants for an additional 20 million shares, reflecting a strategic move to consolidate operations and potentially enhance market positioning. The meeting is set for November 18, 2025, and will be held virtually.

The most recent analyst rating on (SONN) stock is a Sell with a $3.50 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.

Spark’s Take on SONN Stock

According to Spark, TipRanks’ AI Analyst, SONN is a Underperform.

Sonnet BioTherapeutics Holdings is facing severe financial difficulties, with declining revenues, negative profitability, and high leverage being the most significant concerns. Technical analysis shows mixed signals, with some potential for short-term recovery. However, the poor valuation due to negative earnings and lack of dividends further weighs down the stock’s attractiveness.

To see Spark’s full report on SONN stock, click here.

More about Sonnet BioTherapeutics Holdings

Sonnet BioTherapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development of innovative biologic drugs. The company is involved in creating targeted therapies for cancer treatment, leveraging its proprietary platform to enhance the efficacy of biologic drugs.

Average Trading Volume: 899,400

Technical Sentiment Signal: Sell

Current Market Cap: $33.73M